Cullinan Management Inc (CGEM) Stock Price

8.55 ▲ +0.28 (+3.39%)
Open: 8.13 Vol: 1M Day's range: 7.93 - 8.84 Nov 14, 16:00 EST
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
CGEM Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL BUY BUY BUY BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 8.58▼ 8.65▼ 8.59▼ 8.08▲ 8.00▲
MA10 8.62▼ 8.60▼ 8.44▲ 7.75▲ 7.20▲
MA20 8.66▼ 8.41▲ 8.36▲ 7.93▲ 7.43▲
MA50 8.60▼ 8.20▲ 7.81▲ 7.13▲ 8.56▼
MA100 8.43▲ 7.77▲ 7.86▲ 7.41▲ 12.95▼
MA200 8.36▲ 7.86▲ 7.80▲ 7.92▲ 12.17▼
  5 mins 30 mins Hourly Daily Weekly
MACD -0.023▼ 0.013▲ 0.008▲ 0.033▲ 0.279▲
RSI 40.327▼ 56.550▲ 61.811▲ 59.612▲ 53.949▲
STOCH 7.181▼ 69.234     76.779     58.309     65.312    
WILL %R -85.714▼ -32.022     -32.022     -13.756▲ -19.269▲
CCI -147.447▼ 42.704     84.100     102.748▲ 86.240    
Latest Filters Detected On CGEM
▲ RSI&MACD $CGEM MACD cross and RSI above 55 Set Alert
▲ MA $CGEM MA(20) Crossed Above MA(200) Set Alert
▲ MACD $CGEM MACD(12,26,9) Crossed Above Signal Line Set Alert
Cullinan Management Inc News
Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting
Monday, November 10, 2025 05:02 AM
Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company accelerating potential high-impact therapies in autoimmune diseases and cancer, today announced its management team ...
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Thursday, November 06, 2025 04:20 AM
Promising Phase 1 clinical data for CLN-049, a FLT3xCD3 bispecific T cell engager, demonstrating ~30% CRc rate in heavily pretreated, all-comer population of patients with relapsed/refractory AML to ...
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at ...
Monday, November 03, 2025 02:48 PM
CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, regardless of FLT3 mutational status ~30% CRc rate ...
CGEM historical stock data
date open high low close volume
14/11/25 8.13 8.84 7.93 8.55 1,002,179
13/11/25 8.26 8.44 8.09 8.27 648,997
12/11/25 7.80 8.49 7.72 8.35 696,668
11/11/25 7.39 7.885 7.25 7.80 643,907
10/11/25 7.47 8.00 7.38 7.44 631,847
07/11/25 7.24 7.25 6.7318 7.19 712,027
06/11/25 7.38 7.82 7.06 7.35 617,808
05/11/25 7.39 7.52 7.17 7.31 633,275
04/11/25 7.80 7.80 7.36 7.40 702,228
03/11/25 8.57 8.77 7.76 7.81 755,439
Quote Details
52wk Low:5.68
52wk High:14.145
Vol:1M
Avg Vol(3m):18.5M
1Y Chng:-35.08%
1M Chng:+46.40%
Add to Watch List
More Information
Index US Composite
Market Cap. 488.56M